Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-29T10:44:49.278Z Has data issue: false hasContentIssue false
  • English
  • Français

Cognitive Impairment in Schizophrenia and Implications of Atypical Neuroleptic Treatment

Published online by Cambridge University Press:  07 November 2014

Philip D. Harvey  and
Richard S. E. Keefe
Get access Rights & Permissions [Opens in a new window]

Abstract

Cognitive impairment is considered a central feature of schizophrenia. Many aspects of cognition are impaired in schizophrenia. Careful evaluation of the relationship between cognitive impairment and the other symptoms of schizophrenia has revealed several important findings. In this article, we discuss these findings, the effects of typical neuroleptic therapy on cognitive impairment, and important issues to address in cognitive enhancement studies in schizophrenia.

Type
Feature Article
Information
CNS Spectrums , Volume 2 , Issue 8: The Maze of Cognitive Dysfunction , September 1997 , pp. 41 - 55
Copyright
Copyright © Cambridge University Press 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Kraepelin, E. Dementia Praecox and Paraphrenia. Edinburgh, Scotland: E. & S. Livingstone; 1919.Google Scholar
2.Hunt, JM, Cofer, C. Psychological deficit. In: Hunt, JM, ed. Personality and Behavior. New York, NY: Ronald Press; 1944:971–1032.Google Scholar
3.Saykin, AJ, Gur, RC, Gur, RE, et al. Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiatry. 1991:48;618–623.Google Scholar
4.Perlick, D, Stastny, P, Mattis, S, Teresi, J. Contribution of family, cognitive, and clinical dimensions to long-term outcome in schizophrenia. Schizophr Res. 1992;6:257–265.CrossRefGoogle ScholarPubMed
5.Young, DA, Davila, R, Scher, H. Unawareness of illness and neuropsychological performance in schizophrenia. Schizophr Res. 1993;10:117–124.Google Scholar
6.Amador, XF, Strauss, DH, Yale, SA, et al. Awareness of illness in schizophrenia. Schizophr Bull. 1991;17:113–132.CrossRefGoogle ScholarPubMed
7.Medalia, A, Gold, J, Merriam, A. The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol. 1988;3:249–271.Google Scholar
8.Spohn, HE, Strauss, ME. Relation of neuroieptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol. 1989;98:478–486.CrossRefGoogle ScholarPubMed
9.Walker, E, Green, MF. Motor proficiency and attention-task performance by schizophrenic patients. J Abnorm Psychol. 1982;91:261–268.CrossRefGoogle Scholar
10.Earle-Boyer, EA, Serper, MR, Davidson, M, et al. Auditory and visual continuous performance tests in medicated and unmedicated schizophrenic patients: clinical and motoric correlates. Psychiatry Res. 1991;37:47–56.Google Scholar
11.Strauss, ME, Reynolds, KS, Jayaram, G, et al. Effects of anticholinergic medication on memory in schizophrenia. Schizophr Res. 1990;3:127–129.Google Scholar
12.Davidson, M, Harvey, PD, Powchik, P, et al. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am J Psychiatry. 1995:152;197–207.Google ScholarPubMed
13.Addington, J, Addington, D, Maticka-Tyndale, E. Cognitive functioning and positive and negative symptoms in schizophrenia. Schizophr Res. 1991;4:123–134.CrossRefGoogle Scholar
14.Putnam, KM, Harvey, PD, Parrella, M, et al. Symptom stability in geriatric chronic schizophrenic inpatients: a one-year follow-up study. Biol Psychiatry. 1996;39:92–99.Google Scholar
15.Harvey, PD, Lombardi, J, Leibman, M, et al. Cognitive impairment and negative symptoms in schizophrenia: a prospective study of their relationship. Schizophr Res. 1996;22:223–231.Google Scholar
16.Left, JP, Thornicroft, G, Coxhead, N, et al. The TAPS Project. 22: a five-year follow-up of long stay psychiatric patients discharged to the community. Br J Psychiatry. 1994;165:(suppl 25):13–17.Google Scholar
17.Green, MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321–330.Google Scholar
18.Hoffman, RE, Stopek, S, Andreasen, NC. A discourse analysis comparing manic versus schizophrenic speech disorganization. Arch Gen Psychiatry. 1986;43:831–838.Google Scholar
19.Harvey, PD. Speech competence in manic and schizophrenic psychoses: the association between clinically rated thought disorder and cohesion and reference performance. J Abnorm Psychol. 1983;92:368–377.Google Scholar
20.Spitzer, M. The psychopathology, neuropsychology, and neurobiology of associative and working memory in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 1993;243:57–70.CrossRefGoogle ScholarPubMed
21.Goldberg, TE, Gold, JM, Greenberg, R, et al. Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery. Am J Psychiatry. 1993;150:1355–1362.Google ScholarPubMed
22.Knight, RA, Roff, JD, Barrnet, J, et al. Concurrent and predictive validity of thought disorder and affectivity: a 22 year followup of acute schizophrenics. J Abnorm Psychol. 1979;88:1–12.Google Scholar
23.Keefe, RS, Mohs, RC, Losonczy, MF, et al. Characteristics of very poor outcome schizophrenia. Am J Psychiatry. 1987;144:889–895.Google Scholar
24.Breier, A, Schreiber, JL, Dyer, J, Pickar, D. National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Arch Gen Psychiatry. 1991;48:239–246.CrossRefGoogle ScholarPubMed
25.Harvey, PD, Davidson, M, Mueser, K, et al. The Social Adaptive Functioning Evaluation: an assessment measure for geriatric psychiatric patients. Schizophr Bull.. 1997;23:131–146.Google Scholar
26.Heaton, RK, Drexler, M. Clinical neuropsychological findings in schizophrenia and aging. In: Miller, NE, Cohen, GD, eds. Schizophrenia and Aging. New York, NY: Gulford Press; 1987;145–161.Google Scholar
27.Bergman, A, Harvey, PD, Mitroupolou, V, et al. Learning and memory in patients with schizotypal personality disorder. Schizophr Bull.. In press.Google Scholar
28.Harvey, PD, Mohs, RC, Keefe, RSE, et al. Information processing markers of vulnerability to schizophrenia: performance of patients with schizotypal and nonschizotypal personality disorders. Psychiatry Res. 1996;60:49–56.CrossRefGoogle Scholar
29.Voglmaier, MM, Seidman, LJ, Salisbury, D, et al. Neuropsychological dysfunction in schizotypal personality disorder: a profile analysis. Biol Psychiatry. 1997;41:530–540.Google Scholar
30.Oltmanns, TF, Ohayon, J, Neale, JM. The effect of medication and diagnostic criteria on distractibility in schizophrenia. J Psychiatr Res. 1979;14:81–91.Google Scholar
31.Harvey, PD, Pedley, M. Auditory and visual distractibility in schizophrenics: clinical and medication status correlations. Schizophr Res. 1989;2:295–300.CrossRefGoogle ScholarPubMed
32.Marder, SR, Asarnow, RF, van Putten, T. Information processing and neuroleptic response in acute and stabilized schizophrenic patients. Psychiatry Res. 1984;13:41–49.Google Scholar
33.Serper, MR, Davidson, M, Harvey, PD. Attentional predictors of clinical change during neuroleptic treatment. Schizophr Res. 1994;13:65–71.Google Scholar
34.Asarnow, RF, Marder, SR, Mintz, J, et al. Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good and poor information-processing abilities. Arch Gen Psychiatry. 1988;45:822–826.Google Scholar
35.Harvey, PD, Docherty, NM, Serper, MR, et al. Cognitive deficits and thought disorder: II. An eight-month followup study. Schizophr Bull.. 1990;16:147–156.Google Scholar
36.Asarnow, RF, MacCrimmon, DJ. Residual performance deficit in clinically remitted schizophrenics: a marker of schizophrenia? J Abnorm Psychol. 1978;87:597–608.Google Scholar
37.Harvey, PD, Winters, KC, Weintraub, S, et al. Distractibility in children vulnerable to psychopathology. J Abnorm Psychol. 1981;90:298–304.Google Scholar
38.Serper, MR, Bergman, RL, Harvey, PD. Medication may be required for the development of automatic information processing in schizophrenia. Psychiatry Res. 1990;32:281–288.Google Scholar
39.Granholm, E, Asarnow, RF, Marder, SR. Controlled information resources and the development of automatic detection responses in schizophrenia. J Abnorm Psychol. 1991;100:22–30.Google Scholar
40.Granholm, E, Asarnow, RF, Marder, SR. Dual task performance operating characteristics, resource limitations, and automatic processing in schizophrenia. Neuropsychology. 1996;10:3–11.CrossRefGoogle Scholar
41.Hegarty, JD, Baldessarini, RJ, Tohen, M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151:1409–1416.Google Scholar
42.Cooper, LE, Kendell, RE, Gurland, BJ, et al. Psychiatric Diagnosis in New York and London. London, England: Oxford University Press; 1972.Google Scholar
43.Wyatt, RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull.. 1991;17:325–351.Google Scholar
44.Wyatt, RJ. Research in schizophrenia and the discontinuation of antipsychotic medications. Schizophr Bull.. 1997;23:3–10.Google Scholar
45.Carpenter, WT Jr.The risk of medication-free research. Schizophr Bull.. 1997;23:11–18.Google Scholar
46.Loebel, MD, Lieberman, JA, Alvir, JM, et al. Duration of psychosis and outcome in first episode schizophrenia. Am J Psychiatry. 1992;149:1183–1189.Google Scholar
47.Bilder, RM, Lipshitz-Broch, L, Reiter, G, et al. Intellectual deficits in first episode schizophrenia: evidence for progressive deterioration. Schizophr Bull.. 1992;18:437–448.Google Scholar
48.Saykin, AJ, Shtasel, DL, Gur, RE, et al. Neuropsychological deficits in neuroleptic naive first episode patients with schizophrenia. Arch Gen Psychiatry. 1994;51:124–131.Google Scholar
49.Kaplan, HI, Sadock, BJ. Synposis of Psychiatry. 6th ed. Baltimore, Md: Williams and Wilkins; 1991.Google Scholar
50.Mortimer, JA, Ebbitt, B, Jun, AP, et al. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology. 1992;42:1689–1696.CrossRefGoogle ScholarPubMed
51.Green, CR, Mohs, RC, Schmeidler, J, et al. Functional decline in Alzheimer's disease: a longitudinal study. J Am Geriatr Soc. 1993;41:654–661.CrossRefGoogle ScholarPubMed
52.Teri, L, Borson, S, Kiyak, A, et al. Behavioral disturbance, cognitive dysfunction and functional skill: prevalence in relationship in Alzheimer's disease. J Am Geriatr Soc. 1989;37:109–116.Google Scholar
53.Jeste, DV, Wragg, RE, Salmon, DP, et al. Cognitive deficits of patients with Alzheimer's Disease with and without delusions. Am J Psychiatry. 1992;149:184–189.Google Scholar
54.Mohs, RC. Neuropsychological assessment of patients with Alzheimer's Disease. In: Bloom, FE, Kupfer, DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995;1377–1388.Google Scholar
55.Lee, MA, Thompson, PA, Meltzer, HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry. 1994;55:82–87.Google Scholar
56.Gallhofer, B, Bauer, U, Lis, S, et al. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol. 1996;6(suppl):S2–13–S2-20.Google Scholar
57.Berridge, CW, Arnsten, AF, Foote, SL. Noradrenergic modulation of cognitive function: clinical implications of anatomical, electrophysiological, and behavioural studies in animal models. Psychol Med. 1993;23:557–564.Google Scholar
58.Almaric, M, Koob, GF. Functionally selective neurochemical afferents and efferents of the mesocorticolimbic and nigrostriatal dopamine systems. Prog Brain Res. 1993;99:209–226.Google Scholar
59.Gold, JM, Carpenter, C, Randolph, C, et al. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry. 1997;54:159–168.CrossRefGoogle ScholarPubMed
60.Sahakian, BJ, Coull, JT. Tetrahydroaminoacridine (THA) in Alzheimer's Disease: an assessment of attentional and mnemonic function using CANTAB. Acta Neurol Scand. 1993;88:29–35.CrossRefGoogle Scholar
61.Serper, MR, Harvey, PD. Attentional predictors of clinical change: II. Continuous Performance Test predictors of the rate of clinical change. Cognitive Neuropsychiatry. In press.Google Scholar
62.McGlashan, TH. A selective review of recent North American long-term follow-up studies of schizophrenia. Schizophr Bull.. 1988;14:515–542.Google Scholar
63.Lieberman, JA, Kinon, BJ, Loebel, AD. Dopaminergic mechanisms of idiopathic and drug-induced psychosis. Schizophr Bull.. 1990;16:97–110.Google Scholar
64.Loebel, AD, Lieberman, JA, Alvir, JM, Mayerhoff, DI, Deisler, SH, Szymanski, SR. Duration of psychosis and outcome in first episode schizophrenia. Am J Psychiatry. 1992;149:1183–1188.Google Scholar
65.Wyatt, RJ. Early intervention for schizophrenia: can the course of illness be altered? Biol Psychiatry. 1995;38:1–3.Google Scholar
66.Lieberman, JA, Alvir, JM, Koreen, A, et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology. 1996;14(suppl):13S–21S.Google Scholar
67.Carpenter, WT Jr.Serotonin-dopamine agonists and the treatment of negative symptoms. J Clin Psychopharmacol. 1995;15(suppl 1):30S–35S.Google Scholar
68.Van, Putten T, Marder, SR, Mintz, J. A controlled dose study of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry. 1990;47:754–758.Google Scholar